Good morning, everyone, and welcome to Vimian. Vimian's third quarter earnings call.
I'm the CFO and interim CEO. And with me today is Magnus Shelby, who's leading Specialty Pharma, our largest segment representing almost 50% of Vimian.
We'll go through the quarterly results, and Magnus will give you some additional insights into our Specialty Pharma segment. We delivered strong revenue growth of 19% with 9% organic growth in the third quarter.
We also observed strong earnings growth with adjusted EBITDA increasing by 17% in the quarter. Both Specialty Pharma and Veterinary Services continue to deliver strong performance, and our MedTech segment returned to organic growth in the quarter after a tougher second quarter this year.
In August, we received positive news in the US indemnification dispute. The court awarded us $40.2 million in damages, which means that we're entitled to compensation exceeding the amount we paid in the settlement with the patients in 2023.
Our M&A pipeline continues to build, and we're working hard to progress key targets in the pipeline. Turning to the numbers. And looking at the past years, Vimian has a strong track record of growth and profitability, with 16% compounded annual revenue growth and 14% adjusted EBITDA CAGR between 2022 and the third quarter of 2025.
For the third quarter, we reported 19% total revenue growth, reaching €104.3 million.
Organic growth in the quarter was 9%, driven by strong performance in Specialty Pharma and Veterinary Services, and it was also satisfying to see MedTech return to organic growth of 5% in the quarter. In total, we had a 40% contribution from acquisitions and a 4% negative impact from currency movements in the quarter, predominantly from US to euro movements. We delivered strong adjusted EBITDA growth of 17% in the quarter, reaching €25.5 million. Margin was 24.5% compared to 25.0% in the same period last year, negatively impacted by our investments in the commercial organization in MedTech, orthopedics, and the consolidation of the dental business iM3, which has a different financial profile with a headline overview. I will hand over to Magnus for an update on Specialty Pharma, followed by a walkthrough of the other segments and financials. Thank you, Juan, for Specialty Pharma.
We are pleased to deliver another quarter of all-time high revenues for an individual quarter.
We delivered double-digit organic growth of 11% with growth across all four therapeutic areas. The strongest contribution this quarter came from Specialty Pharmaceuticals and specialized nutrition. New products, new contracts with corporate clients, and internationalization were key growth drivers in specialized nutrition.
We had the opportunity to launch another national campaign across the US with one of the leading retailers, which supported growth in the quarter. Adjusted EBITDA grew organically by 14% and we had a 150 basis points margin improvement, driven by strong revenue growth and a good drop-through to the bottom line. Turn to the next page.
I will put Q3 performance into context. We have a two-pronged strategy: organic and M&A-driven growth. Our organic growth strategy revolves around three pillars: cross-selling, innovation, and education. Cross-selling. We currently have 16 cross-selling initiatives ongoing, representing 18% of sales. A key initiative has been to nationalize our portfolio by going direct with our own sales force, as opposed to using a distributor. Our acquisition of ICF in 2020 is a case in point.
ICF has a great topical product range, strong brands, and a significant presence in Italy, with proprietary production. It is very synergistic with our ally range but largely remains an Italian phenomenon, relying upon third-party distributors. Outside of Italy, we have internationalized the business by terminating the distribution contracts for the veterinary channel in France, the Netherlands, and Belgium. We now go direct with our own sales force in these markets.
We have also expanded our channel presence.
We have launched a range online in the UK, Scandinavia, Germany, and France.
All in all, we have grown the international business of ICF during our ownership by 18% CAGR in Q3. Our internationalization and channel expansion initiatives of the ICF range continued with good momentum.
60% of cross-selling growth came from these ICF initiatives.
Innovation.
We launched 21 products in Q3 and currently have 70 products in the pipeline. Innovations in antimicrobial autophagy continue to be important.
Our antimicrobial autophagy range typically substitutes antibiotics. Additionally, it is highly synergistic with our existing range. 50% of all dogs get otitis as a secondary infection.
In Q3, we launched a follow-up to our bestseller called ATF4.
It reduces bacterial growth in the ear canal. It includes two novel peptides, which we have patented.
Also, the composition ensures a slow-release function so it lasts between applications.
Education. We attended 30 congresses in Q3. A key highlight was the British Equine Veterinary Association Congress in Birmingham, where we were a gold sponsor.
We were also the gold sponsor at the European Society of Veterinary Dermatology Congress in Bilbao.
Pet EBITA 4 was an important launch at the Congress, and we continue to promote the advantages of our molecular testing platform. Pet explorer packs were featured at the Congress. M&A, the prospects for mergers and acquisitions are strong. Our industry remains highly fragmented. We are taking our business from €4 million of sales at inception ten years ago to more than €180 million today, a growth of 45x, and M&A has been an important tool for the trajectory. M&A will continue to be an important tool going forward. Year to date, we have screened more than 235 targets in existing and new therapeutic areas, a testament to the fragmentation of the industry. More M&A will also unlock additional cross-selling opportunities.
Turning to the next page, I will provide more color on cross-selling.
39% of year-to-date organic growth comes from cross-selling.
Increased direct market presence and utilization have been the main contributors, accounting for 49%. Channel expansion contributed 35%. And the remainder has come from substituting third-party products with our own products.
Our cross-selling strategy going forward rests on three pillars: grow existing cross-selling initiatives.
Launch new cross-selling initiatives.
We have eight set to be launched in 2026 and plan to create new cross-selling initiatives from M&A. I will now hand back to you.
Thank you very much, Magnus. Let me give you some insights into the other three segments of Vimian, starting with MedTech, where MedTech delivered 46% total revenue growth and 5% organic growth, driven by mid to high single-digit growth in orthopedics in Europe and Asia Pacific, combined with flat development in North America, which is a recovery from the second quarter this year.
Although I'm pleased with the recovery in US orthopedics during the quarter, the surgery market is likely to remain soft over the coming period. I'm confident that we are operationally taking the right actions and now have a strengthened team in place for the long term. This is a very attractive market with millions of untreated animals and opportunities to educate more veterinarians to unlock growth.
Our dental operations with iM3 and the two bolt-on acquisitions completed earlier this year continue to deliver solid growth in the quarter. In the beginning of October, we completed a small acquisition of AI-enabled imaging software that further complements and strengthens our dental portfolio.
Adjusted EBITDA grew 26% in the quarter, and the year-over-year margin in MedTech was impacted by our investments in the commercial organization in US orthopedics to drive growth and the consolidation of iM3 from the 1st of October last year.
All in all, the third quarter marked an important step in the right direction for our US orthopedics business, and our dental operations continue to show good performance.
Veterinary Services continue to perform well with 11% organic growth, driven by new member growth and increased penetration of services across the member base. The total number of member clinics reached 9,940 at the end of the quarter. The margins showed a sequential improvement, but a year-over-year decline as we now start to initiate planned investments in new geographies and services, which we will see more of in the coming quarters. Adjusted EBITDA for the third quarter grew by 4%.
Overall, we're satisfied with the continued good momentum in Veterinary Services. Diagnostics delivered 4% organic growth despite a lower level of disease outbreaks compared to the same period last year. Year to date, the segment delivered 13% organic growth.
The margin reflects our investments in new products to diversify into the companion animal market, and we are also exploring M&A opportunities to strengthen our offering within the companion animal diagnostics space. Before I go deeper into the quarterly financials, I want to give you a brief summary of M&A activities and the important role they have played in executing our strategy and continuing to build Vimian as a leading player in the global animal health industry. M&A continues to form an integral part of our strategy, and we're now accelerating our efforts to advance and progress our pipeline, covering both existing platforms and new market niches. In the past five years, we have completed 44 acquisitions, adding approximately €170 million in revenue across all four segments and spread across the key regions of North America, Europe, and Asia Pacific. In the past 12 months, we have completed four acquisitions in veterinary dental, adding €47 million in revenues.
Veterinary dentistry is a new market niche for us and one of the fastest-growing categories in veterinary clinics. Today, 80% of adult dogs and cats suffer from periodontal disease, and we see significant white space here. Looking ahead, we'll continue to build on this platform.
We have established a strong network among entrepreneurs in the dental space.
We also continue to execute on our sustainability agenda focused on animals, our people, and the planet.
During the third quarter, our efforts in this area were recognized when we achieved improved ESG ratings with Sustainalytics to low risk. And earlier this year, MSCI upgraded our rating to AA.
With that business review, let me give you a walkthrough of the financials for the third quarter. Adjusted EBITDA in the third quarter was €25.5 million, an increase of 17%. This represents a margin of 24.5%. The lower margin compared to the same period last year is driven by our investments in the commercial organization in US orthopedics to drive growth and the consolidation of iM3.
From October 1st last year, with a lower margin profile, we report an operating profit of €17.5 million, a significant 74% increase from last year's result of €10.1 million. Items affecting comparability decreased in the quarter and totaled €1.7 million, with the largest contribution from MedTech relating to M&A.
The net financial items of -€4.1 million consist of three main components. Finance expense of -€4 million, with an average interest rate of 4.6%, the quarterly discounting impact of -€0.8 million, and an impact of €1.3 million from profitability adjustments on contingent considerations. And lastly, a negative impact of €1 million from exchange rate effects on revaluation of debt. The income tax expense for the quarter amounted to -€6.6 million, inflated by additional taxes paid for the reassessment of prior year taxes in one of our entities. We're currently reviewing tax management in the group to, over time, reduce our effective tax rate overall.
This results in a profit for the period of €6.8 million, with earnings per share of 1 cent for the quarter. Cash flow from operating activities reached €10.8 million in the third quarter, impacted by the higher tax expenses in the quarter and a negative impact from currency effects. Net working capital amounted to €102.2 million at the end of the quarter, which is equal to 24% of revenue, and the €102.2 million is an increase from €99.5 million at the end of June, which represented 25% of revenue. So in relation to sales, net working capital decreased slightly in the quarter. The majority of the increase in working capital is mainly related to lower trade payables. Cash flow from investing activities amounted to -€5.1 million, driven by investments in intangible assets and equipment, and the cash flow from financing activities of -€22 million is related to the repayment of borrowings. After the end of the quarter.
We received the first payment of approximately $50 million following the court decision in the US indemnification dispute. At the end of the period, net debt amounted to €253.5 million, which is down from €260.6 million at the end of the second quarter. Leverage in the quarter equaled 2.1x. And we remain well-capitalized for future M&A opportunities. In concluding remarks, from a broader perspective.
This will conclude the review for the third quarter, where we delivered strong revenue growth of 19% and 9% organic growth.
We also delivered strong earnings growth with 17% adjusted EBITA growth. Specialty Pharma and Veterinary Services continue to deliver strong performance. Combined with the recovery in MedTech orthopedics.
Looking ahead, we'll continue to implement our actions to strengthen commercial performance in US orthopedics, and we're also accelerating our efforts to expand and progress our M&A pipeline.
Looking at both existing and new market niches, we are focusing on expanding our reach and influence. We see our market continuing to grow with increasing pet ownership, the humanization of pets, and an aging population. I appreciate that we remain well-positioned in the current geopolitical landscape with well-diversified operations. With these concluding remarks, I would like to open up for a Q&A session.